Under the terms of the agreement, Jacobs is providing engineering, procurement and construction management (EPCM) services to increase the site’s production capacity by 70 percent and create a second line of purification that allows for multiple drugs to be manufactured simultaneously.
Already one of the world’s largest production facilities for monoclonal antibodies from mammalian cells, the expansion project adds cell culture bioreactors to the site.
Jacobs’ services are being led from its operations in Milan, Italy.
In making the announcement, Jacobs Senior Vice President Life Sciences Robert Norfleet stated, “We look forward to partnering with Novartis on the expansion of its Huningue site. We’re proud to have this opportunity to draw on our extensive global EPCM expertise for a project that can help Novartis improve the lives of people who depend on its treatments.”
The $100 million expansion project is scheduled to be completed in four years.
Jacobs is one of the world’s largest and most diverse providers of full-spectrum technical, professional and construction services for industrial, commercial and government organizations globally. The company employs 60,000 people and operates in more than 30 countries around the world. Its Life Sciences business is the largest professional services provider to the pharmaceutical and biotechnology industries. For more information, visit www.jacobs.com.
Statements made in this release that are not based on historical fact are forward-looking statements. We base these forward-looking statements on management’s current estimates and expectations as well as currently available competitive, financial and economic data. Forward-looking statements, however, are inherently uncertain. There are a variety of factors that could cause business results to differ materially from our forward-looking statements. For a description of some of the factors which may occur that could cause actual results to differ from our forward-looking statements please refer to our 2015 Form 10-K, and in particular the discussions contained under Items 1 - Business, 1A - Risk Factors, 3 - Legal Proceedings, and 7 - Management's Discussion and Analysis of Financial Condition and Results of Operations. We do not undertake to update any forward-looking statements made herein.